Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Tekmira Pharmaceuticals Corp Issues FY 2013 Revenue Guidance Below Analysts' Estimates


Monday, 12 Aug 2013 04:00pm EDT 

Tekmira Pharmaceuticals Corp announced that it expects fiscal 2013 revenue to be in the range of $15.0 to $20.0 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $22.2 million for fiscal 2013. 

Company Quote

22.23
-0.97 -4.18%
1:19pm EDT